162 related articles for article (PubMed ID: 11585336)
21. Participation of cathepsin L on bone resorption.
Kakegawa H; Nikawa T; Tagami K; Kamioka H; Sumitani K; Kawata T; Drobnic-Kosorok M; Lenarcic B; Turk V; Katunuma N
FEBS Lett; 1993 Apr; 321(2-3):247-50. PubMed ID: 8477857
[TBL] [Abstract][Full Text] [Related]
22. Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.
Yamashita DS; Xie R; Lin H; Wang B; Shi SD; Quinn CJ; Hemling ME; Hissong C; Tomaszek TA; Veber DF
J Pept Res; 2004 Mar; 63(3):265-9. PubMed ID: 15049838
[TBL] [Abstract][Full Text] [Related]
23. Is cathepsin K truly involved in bone resorption?
Everts V
J Bone Miner Res; 1998 Feb; 13(2):321-2. PubMed ID: 9495527
[No Abstract] [Full Text] [Related]
24. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
[TBL] [Abstract][Full Text] [Related]
25. Natural inhibitors targeting osteoclast-mediated bone resorption.
Zeng GZ; Tan NH; Hao XJ; Mu QZ; Li RT
Bioorg Med Chem Lett; 2006 Dec; 16(24):6178-80. PubMed ID: 17027271
[TBL] [Abstract][Full Text] [Related]
26. Cathepsin B and L activities in isolated osteoclasts.
Rifkin BR; Vernillo AT; Kleckner AP; Auszmann JM; Rosenberg LR; Zimmerman M
Biochem Biophys Res Commun; 1991 Aug; 179(1):63-9. PubMed ID: 1883385
[TBL] [Abstract][Full Text] [Related]
27. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
28. Quantification of the expression levels of lysosomal cysteine proteinases in purified human osteoclastic cells by competitive RT-PCR.
Ishibashi O; Inui T; Mori Y; Kurokawa T; Kokubo T; Kumegawa M
Calcif Tissue Int; 2001 Feb; 68(2):109-16. PubMed ID: 11310346
[TBL] [Abstract][Full Text] [Related]
29. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
[TBL] [Abstract][Full Text] [Related]
30. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
[TBL] [Abstract][Full Text] [Related]
31. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
32. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
[TBL] [Abstract][Full Text] [Related]
33. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis.
Kim TS; Tasker AS
Curr Top Med Chem; 2006; 6(4):355-60. PubMed ID: 16611147
[TBL] [Abstract][Full Text] [Related]
34. Effect of cathepsin K inhibitors on bone resorption.
Teno N; Masuya K; Ehara T; Kosaka T; Miyake T; Irie O; Hitomi Y; Matsuura N; Umemura I; Iwasaki G; Fukaya H; Toriyama K; Uchiyama N; Nonomura K; Sugiyama I; Kometani M
J Med Chem; 2008 Sep; 51(17):5459-62. PubMed ID: 18707091
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of collagenolytic cathepsins by beta-lactoglobulin in milk and its suppressive effect on bone resorption.
Ogawa N; Takahashi M; Ishidoh K; Katunuma N
J Nutr Sci Vitaminol (Tokyo); 2009 Jun; 55(3):264-70. PubMed ID: 19602835
[TBL] [Abstract][Full Text] [Related]
36. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
37. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
Duplat D; Gallet M; Berland S; Marie A; Dubost L; Rousseau M; Kamel S; Milet C; Brazier M; Lopez E; Bédouet L
Biomaterials; 2007 Nov; 28(32):4769-78. PubMed ID: 17686515
[TBL] [Abstract][Full Text] [Related]
38. Cathepsin K: a therapeutic target for bone diseases.
Zhao Q; Jia Y; Xiao Y
Biochem Biophys Res Commun; 2009 Mar; 380(4):721-3. PubMed ID: 19338743
[TBL] [Abstract][Full Text] [Related]
39. Effect of novel N-cyano-tetrahydro-pyridazine compounds, a class of cathepsin K inhibitors, on the bone resorptive activity of mature osteoclasts.
Kim SH; Jhon DJ; Song JH; No JS; Kang NS
Bioorg Med Chem Lett; 2008 Jul; 18(14):3988-91. PubMed ID: 18571402
[TBL] [Abstract][Full Text] [Related]
40. Regulation of collagenolytic protease secretion through c-Src in osteoclasts.
Furuyama N; Fujisawa Y
Biochem Biophys Res Commun; 2000 May; 272(1):116-24. PubMed ID: 10872813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
